Comparison in the Treatment of Acute Cystitis Using Cephalosporin and Norfloxacin (CECI)

Inclusion Criteria: * Sign, initialize and date the informed consent form * Age ≥ 18 years * For urinary infection diagnosis, the following parameters must be considered in the urine I test: * Leukocyturia: ≥ 15,000 leukocytes * Epidermal cells: \< 20,000/mL * Presence of bacteriuria * Presence of nitrite (positive results) * To have a 2 points score (from 12 points) regarding the following symptoms of acute cystitis: * Dysuria * Urinary urgency * Frequent urination * Pain in the upper area of pubis Each symptom must be scored according to the classification below. Total score may range from 0 to 12 points. Severity Value Absent 0 Mild 1 Moderate 2 Severe 3 Exclusion Criteria: Research subjects that meet any of the criteria below will not be eligible for the study: * Asymptomatic urinary infection or infection in any organ * Documented incidence of UTI in the last year * Symptoms of pyelonephritis (cystitis symptoms plus fever, lower back pain or chills) * History of complicated urinary tract infection (congenital abnormalities, urinary tract distortion or obstruction, formation of calculus in the urinary tract) * Use of catheter in the urinary tract * Chronic renal or hepatic disease * Seizure-related diseases * Neurological deficits that interfere in the urinary flow and tract defense * Decompensated diabetes mellitus (fasting blood glucose ≥ 150 mg/dL); * Immunodepression: * Subjects with the human immunodeficiency virus (HIV) * Chronic use of corticosteroids in a dose ≥ 5 mg/day of prednisone for over 30 days * Any diseases related to immune dysfunction * Severe comorbidities (at the investigator's discretion) * History of allergy to penicillins, cephalosporines or quinolones * Subjects on medications such as antibiotics, amiodarone, antacids or sucralphate, tricyclic antidepressants, antipsychotics, cyclosporine, cisapride, didanosine, erythromycin, fembufeno, gliburide (a sulphonilurea), nitrofurantoin, probenecid, procainamide, quinidine, sotalol, teophylline, warfarin * Treatment due to UTI two weeks before entering study, or on antimicrobial treatment at least 3 times within the last 12 months * Use of phenazopyridine 7 days before entering the study * Hospitalization 30 days before study enrollment * Female research subjects that are pregnant, breastfeeding, or women with childbearing potential that deny to use at least two safe contraceptive methods during study * Participation in another clinical trial in the last 12 months